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The purpose of this study is to assess the role of tumour necrosis factor (TNF) polymorphisms in the risk of developing bladder
cancer and effect on tumour stage, grade and progression. In all, seven single-nucleotide polymorphisms in TNF were studied in 196
bladder cancer patients and 208 controls using a PCR-SSP genotyping technique. It was seen that there was a significant association of
two polymorphisms in TNF with bladder cancer: the TNFþ488A allele was found in 28.1% of patients compared with 14.9% of
controls (P¼0.0012). In addition, TNF 859T was found in 26.0% of patients compared with 14.4% of the controls (P¼0.0036). The
two loci were in tight linkage disequilibrium, that is, almost all the individuals having TNFþ488A also had TNF 859T. Patients with
the TNFþ488A or TNF 859T were more likely to present with a moderately differentiated tumour than those patients without
the uncommon allele. In all, 16.7% of patients with TNFþ488A and 29.9% of patients without TNFþ488A presented with a G1
tumour (P¼0.015). A total of 14% of patients with TNF 859T and 30.5% of patients without TNF 859T presented with a G1
tumour (P¼0.0043). There was no significant effect on time to first recurrence, stage progression or grade progression. In
conclusion, a significant association between TNF polymorphisms TNFþ488A and TNF 859T and risk of bladder cancer was
detected in this study. Both these polymorphisms were associated with grade of tumour at presentation although there was no
significant effect on subsequent tumour behaviour.
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Transitional cell carcinoma (TCC) comprises 90% of all cases of
bladder cancer. An estimated 57400 new cases (42000 men and
15200 women) will be diagnosed with TCC in the USA in 2003. A
total of 12500 people (8600 men and 3900 women) will die of the
disease (Jemal et al, 2003). In all, 70% present with superficial
cancer, but of these 70% recur after treatment and 20–30%
progress to invasive disease (Hassen and Droller, 2000).
Tumour necrosis factor alpha (TNFa) has been implicated in the
development and progression of tumours (Naylor et al, 1992) and
is known to be important in angiogenesis and is a key
proinflammatory cytokine. In high doses, it acts to destroy tumour
vasculature but in low doses its role is analogous to that in
inflammation, acting as a vasodilator and chemoattractant for cells
responsible for the inflammatory response and thus promoting the
development of tumour stroma.
There is considerable direct and indirect evidence to implicate
TNFa in the development of bladder cancer. TNFa-deficient
mice have a greatly reduced skin tumour growth and tumour
induction in response to chemical carcinogens (Moore et al, 1999).
In angiogenesis, TNFa is known to play a key role in the regulation
of the enzyme thymidine phosphorylase (Leek et al, 1998), which
in turn has been demonstrated to be a component in bladder
cancer progression (O’Brien et al, 1996). TNFa has also been
demonstrated in bladder tumour biopsies by immunohistochem-
istry (Sander et al, 1996) and has been shown to be involved in
both the local and systemic immune response to the intravesical
instillation of bacille Calmette-Guerin (BCG) (Taniguchi et al,
1999). Following stimulation with BCG, increased levels of TNFa
protein have been demonstrated in the urine of human patients
(Taniguchi et al, 1999) and increased TNFa mRNA has been
demonstrated in the bladders and spleens of mice (Shin et al,
1995). The importance of TNFa in bladder cancer pathogenesis
raises the possibility that variation in the gene for TNFa (TNF)
may predispose to risk of bladder cancer or alter subsequent
tumour behaviour.
Tumour necrosis factor has been extensively investigated for
genetic variation. The gene for TNFa is found on chromosome 6 in
the class III region of the major histocompatibility complex (MHC)
and is flanked by the lymphotoxin a and b genes. There are 16
known polymorphisms in and around TNF, including five
microsatellites. The two most studied single-nucleotide poly-
morphisms (SNPs) are the promoter polymorphisms  308G/A
and  238G/A. Other polymorphisms that may be of significance
are þ488G/A in the first intron, and the promoter variants,
 1032T/C,  865C/A,  859C/T and  380G/A. There have been
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smany efforts to determine the significance of these polymorphisms
with extensive disease association and functional studies, the
results of which have been conflicting (Allen, 1999; Bidwell et al,
1999).
One of the difficulties with finding an association with any SNP
in the MHC region is the strong, but variable, linkage disequili-
brium. At meiosis, a set of alleles on the same small chromosomal
segment tends to be transmitted as one block, that is, a haplotype.
As a result, any given allele may simply be a marker for another
allele. In addition, an SNP at a given locus in one individual may
be part of a haplotype that has an effect on protein expression or
function, whereas exactly the same SNP in another individual may
not form part of the functional haplotype and no functional effect
is seen.
However, there is clear evidence for individual variation in TNFa
production and considerable evidence supports the association of
the  308 haplotype with high TNFa production (Wilson et al,
1993, 1997).
An association between malignancy and TNF polymorphisms
includes non-Hodgkin’s lymphoma (Warzocha et al, 1998) and
myeloma (Davies et al, 2000). In addition, an association between
two different polymorphisms, TNFþ488, TNF 308, and prostate
carcinoma has been demonstrated (Oh et al, 2000). Studies
demonstrating an association with malignancy and TNF micro-
satellites include colorectal carcinoma (Gallagher et al, 1997) and
laryngeal carcinoma (Matthias et al, 1998).
Given the key role of TNFa in angiogenesis and tumour
development, the aim of this study was to investigate whether
polymorphisms in TNF alter the risk of developing bladder
cancer and subsequent tumour behaviour. We determined
the frequency of these polymorphisms in bladder cancer
patients and a control population, and correlated these results
with the stage and grade of tumour and number of lesions
at presentation and subsequent tumour recurrence and
progression.
METHODS
This prospective study was approved by the Central Oxford
Research Ethics Committee. Consecutive patients with
histologically proven bladder cancer attending the Urology
Department, Churchill Hospital, Oxford between October 1999
and October 2000 were studied. At the time of recruitment,
5ml of peripheral blood was taken in an EDTA tube for DNA.
A clinical database was developed, including patients’
demographic details, previous medical history and family
history of cancer. Findings and treatment at initial presentation
and subsequently throughout cystoscopic surveillance were
recorded, with particular attention to number of lesions, stage
and grade (see Table 1). All tumours were identified with
cystoscopy. They then underwent transurethral resection and the
specimens were examined by histopathologists. This allowed
staging by the 1997 tumour node metastasis (TNM) classification.
Complete clinical records were not available on 11 patients. In five
patients, grade was not available, in 10 the number of lesions was
not recorded and in 11 the stage was not available. All these
patients were eligible for the analysis of polymorphism vs risk of
cancer, but the cases that did not have full histological details were
not included in the analysis for stage and grade and number of
lesions.
DNA was extracted and PCR amplification using a unified
polymerase chain reaction sequence-specific primers (PCR-SSR)
genotyping technique was performed using protocols previously
described (Bunce et al, 1995). Polymerase chain reaction
products were then electrophoresed in 1% agarose gels and
visualised with UV illumination, see Figure 1. Seven SNPs
in TNF: þ488G/A,  238G/A,  308G/A,  1032T/C,  865C/A,
 859C/T and  380G/A were analysed. To determine the
haplotypes of the three most widely studied polymorphisms
(TNFþ488,  238,  308), we adapted a double amplification
refractory mutation system (ARMS) method previously
described (Fanning et al, 1997). This involves four
primer mixes and from the pattern of bands in these
reactions, the individual biallelic polymorphisms can be derived
(Table 2).
A major problem of genetic association studies is the inability
to confirm results in additional cohorts (Editorial, 1999). To
address this, we initially examined a first set of 99 consecutive
bladder cancer patients and compared gene frequencies with a
control population of 107 cadaveric renal transplant donors.
Subsequently, a further 101 controls and 97 bladder cancer
patients were examined. The patients were examined only for the
polymorphisms that showed a positive association in the first set
that is, þ488 (together with  238 and  308) and  859. The
representative nature of the control cohort of the UK population
has been previously described in HLA typing reports (Bunce et al,
1996).
In addition, a set of 91 individuals with histologically confirmed
malignant melanoma was investigated for the same TNF poly-
morphisms. This group served as an additional control population
with malignancy unrelated to the urinary tract.
The results were analysed with the statistical package Knowledge
Seekert (Angoss software, Toronto, Canada).
Table 1 Clinical information for bladder cancer patients (n¼196)
Age
Median (range) (years) 68 (30–92)
Sex
Male 151
Female 45
No. of lesions at initial presentation (n¼186)
1 137
22 6
31 2
431 1
Stage at initial presentation (n¼185)
cis 5
a5 4
18 9
23 3
34
Grade at initial presentation (n¼191)
G1 50
G2 92
G3 49
1 2 3 4 56 78 9 10 11 12
Figure 1 Polyacrylamide gel photograph showing TNF polymorphisms.
Lanes 1–4 correspond to the four reactions used to identify the four
previously documented haplotypes of the three biallelic polymorphisms,
TNFþ488,  238 and  308. The upper visible band is the control band. A
positive reaction is seen in lanes 1 and 2, giving a result of TNFþ488G,
 238G,  308GA. Lanes 5–12 represent the remaining individual biallelic
polymorphisms as follows: lanes 5 and 6: TNF 1032T,C; lanes 7 and 8:
TNF 865C,A; lanes 9 and 10: TNF 859C,T; lanes 11 and 12:
TNF 380G,A. In each case, the lower band is the control band. Positive
reactions are seen in lanes 5,7,9 and 11 giving the result of TNF 1032T,
 865C,  859C, and  380G.
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Frequency of polymorphisms in patients and controls
The presence of TNFþ488A was significantly higher in the first set
of bladder cancer patients compared with controls. It also
approached significance in the second set, remaining significant
with the two sets combined. In the first set, TNFþ488A was found
in 13.1% of controls compared with 28.3% of patients (P¼0.0068)
and in the second set, in 16.8% of controls compared with 27.8% of
patients (P¼0.063, see Table 3). With the two sets combined,
TNFþ488A was seen in 14.9% of controls and 28.1% of patients
(P¼0.0012, see Table 4).
The presence of TNF 859T was significantly higher in the first
set of patients. In the second set, the presence was more frequent
but did not reach significance. Nonetheless, significance was
reached with the two sets combined. In the first set, TNF 859T
was found in 13.1% of controls compared with 26.3% of patients
(P¼0.017) and in the second set, in 15.8% of controls compared
with 25.8% of patients (P¼0.085, see Table 3). With the two sets
combined, TNF 859T was seen in 14.4% of controls and 26.0% of
patients (P¼0.0036, see Table 4). These results were not
independent of each other as the TNFþ488 and TNF 859 loci
were in strong linkage disequilibrium, that is, almost all the
individuals with TNFþ488A also had TNF 859T.
No significant associations between the TNF polymorphisms
and melanoma were detected (Table 4).
Association with stage and grade at presentation
Information on grade of tumour at presentation was available on
191 patients. There was a significant association between the
grade of tumour at initial presentation and the polymorphisms
TNF 859T (P¼0.0043) and TNFþ488A (P¼0.015, see Table 5).
Thus, those patients who had the uncommon allele at TNFþ488
and TNF 859 were more likely to present with a moderately
differentiated (Grade 2) tumour than those patients without the
uncommon allele. Of 191 patients for whom clinical information
was available, 50 (26.2%) presented with a G1 tumour, 92
(48.2%) with a G2 and 49 (25.6%) with a G3 (Table 5) tumour.
Of the 50 patients with TNF 859T, seven (14%) presented
with a G1 tumour. Of the 141 patients without TNF 859T,
43 (30.5%) presented with a G1 tumour. Although there
were more G2 tumours in the TNF 859T group, there were fewer
G3. w
2 tests were carried out for tumour distribution in three
categories and also performed with G2 and G3 combined as a
single group, G1 vs G2þG3. This showed that the distribution into
the three categories separately was highly significant (P¼0.0043)
Table 2 PCR-SSP primer sequences, specificities and primer mix composition
Sense primer
Conc
(mM) Antisense primer
Conc
(mM)
Amplicon
size
TNF+488G/ 238G/ 308G 50-g C A T C C C C g T C T T T C T C C A C 0.51 50 A T A g g T T T T g A g g g g C A T g g 0.51 835
TNF+488G/ 238G/ 308A 50- gCATCCCCgTCTTTCTCCAC 1 . 7 5 0 ATAggTTTTgAggggCATgA 1 . 7 8 3 5
TNF+488G/ 238A/ 308G 50-g C A T C C C C g T C T T T C T C C A C 0.85 50 g A A g A C C C C C C T C g g A A T C A 0.85 763
TNF+488A/ 238G/ 308G 50-g C A T C C C C g T C T T T C T C C A T 0.51 50 g A A g A C C C C C C T C g g A A T C g 0.51 763
TNF 1032T 50-C C g g g A A T T C A C A g A C C C C 3.4 50- CAAAggAgAAgCTgAgAAgAT 3 . 4 4 3 3
TNF 1032C 50-C C g g g A A T T C A C A g A C C C C 3.4 50- CAAAggAgAAgCTgAgAAgAC 3 . 4 4 3 3
TNF 865C 50-C C g g g A A T T C A C A g A C C C C 3.4 50-C g A g T A T g g g g A C C C C C C 3.4 263
TNF 865A 50-C C g g g A A T T C A C A g A C C C C 3.4 50-g A g T A T g g g g A C C C C C A 3.4 262
TNF 859C 50-C T A C A T g g C C C T g T C T T C g 5.1 50-A A g g A T A A g g g C T C A g A g A g 5.1 270
TNF 859T 50-T C T A C A T g g C C C T g T C T T C A 5.1 50-A A g g A T A A g g g C T C A g A g A g 5.1 270
TNF 380G 50- ggCTgggTgTgCCAACAAC 3 . 4 5 0-C C T g C A T C C T g T C T g g A A g 3.4 396
TNF 380A 50- ggCTgggTgTgCCAACAAC 3 . 4 5 0-T C C T g C A T C C T g T C T g g A A A 3.4 397
Table 3 Phenotype frequencies for bladder cancer patients and controls; first and second sets
First set controls (n¼107) First set patients (n¼99) Second set controls (n¼101) Second set patients (n¼97)
TNF+488G 107 100.0% 99 100.0% 100 99.0% 95 97.9%
TNF+488A 14 13.1% 28 28.3% P¼0.0068 17 16.8% 27 27.8% P¼0.063
TNF 238G 106 99.1% 99 100.0% 100 99.0% 97 100.0%
TNF 238A 17 15.9% 3 3.0% P¼0.0018 4 4.0% 18 18.6% P¼0.0011
TNF 308G 106 99.1% 98 99.0% 97 96.0% 95 97.9%
TNF 308A 33 30.8% 35 35.4% P¼0.49 36 35.6% 21 21.6% P¼0.0030
TNF 1032T 99 92.5% 97 98.0% 99 98.0%
TNF 1032C 47 43.9% 36 36.4% P¼0.27 32 31.7%
TNF 865C 105 98.1% 98 99.0% 100 99.0%
TNF 865A 32 29.9% 26 26.3% P¼0.56 27 26.7%
TNF 859C 107 100.0% 99 100.0% 99 98.0% 95 97.9%
TNF 859T 14 13.1% 26 26.3% P¼0.017 16 15.8% 25 25.8% P¼0.085
TNF 380G 107 100.0% 99 100.0% 101 100.0%
TNF 380A 4 3.7% 0 0.0% P¼0.05 1 1.0%
The significant results TNF+488 and TNF 859 are highlighted with a grey background.
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in the TNF 859T polymorphism group (P¼0.023).
Of the 54 patients with the TNFþ488A polymorphism, nine
(16.7%) presented with a G1 tumour. Of the 137 patients who did
not carry this variant, 41 (29.9%) presented with a G1 tumour.
Again, w
2 tests were performed for tumour distribution in three
categories and also performed with G2 and G3 combined as a
single group. This showed that the distribution into the three
categories separately was significant (P¼0.015). When G2 and G3
were considered together, that is, G1 vs G2þG3, the association
approached significance (P¼0.06), see Table 5.
No association was found with polymorphisms and stage at
presentation.
Association with number of lesions at presentation
No association was found with polymorphisms and number of
lesions at presentation.
Association of TNFþ488A and TNF 859T polymorphisms
with prognosis
The log-rank test showed no association of TNFþ488A or
TNF 859T on time to first recurrence (TNFþ488A, P¼0.57,
TNF 859T, P¼0.41), time to first stage progression (TNFþ488A,
P¼0.69, TNF 859T, P¼0.79) or on time to first grade progres-
sion (TNFþ488A, P¼0.26, TNF 859T, P¼0.12). The median
time of follow-up from first diagnosis was 3.65 years. The range
was 0.06–35.8 years.
DISCUSSION
The role of TNF polymorphisms in the risk of bladder cancer,
bladder cancer phenotype and subsequent tumour behaviour was
assessed in this study. We have shown for the first time a
significant association of the TNF polymorphisms TNFþ488A and
TNF 859T and risk of bladder cancer. The TNFþ488A has been
previously associated with rheumatoid arthritis (Kaijzel et al, 1998;
Verweij, 1999) and common variable immunodeficiency (Mulligh-
an et al, 1997) in addition to prostate cancer (Oh et al, 2000). At
position TNF 859, no disease association studies have been
reported and functional studies have been conflicting with Higuchi
et al (1998) showing an effect on TNF transcription, while
Uglialoro et al (1998) showed no effect.
In addition to the association of TNFþ488A and TNF 859T
with risk of bladder cancer, we have shown for the first time a very
strong linkage disequilibrium between these two sites in bladder
cancer patients, normal controls and melanoma patients. The
linkage disequilibrium between TNFþ488A and TNF 859T
Table 4 Phenotype frequencies for combined controls, bladder cancer and melanoma patients
Controls n¼208 Patients n¼196/99 Melanoma n¼91
TNF+488G 207 208 99.5% 194 196 99.0% 91 91 100%
TNF+488A 31 208 14.9% 55 196 28.1% P¼0.0012 13 91 14% P¼0.89
TNF 238G 206 208 99.0% 196 196 100.0% 91 91 100%
TNF 238A 21 208 10.1% 21 196 10.7% P¼0.84 8 91 8.80% P¼0.76
TNF 308G 203 208 97.6% 193 196 98.5% 90 91 99%
TNF 308A 69 208 33.2% 56 196 28.6% P¼0.32 34 91 37% P¼0.48
TNF 1032T 198 208 95.2% 97 99 98.0% 89 91 98%
TNF 1032C 79 208 38.0% 36 99 36.4% P¼0.78 35 91 38% P¼0.94
TNF 865C 205 208 98.6% 98 99 99.0% 89 91 98%
TNF 865A 59 208 28.4% 26 99 26.3% P¼0.70 27 91 30% P¼0.82
TNF 859C 206 208 99.0% 194 196 99.0% 91 91 100%
TNF 859T 30 208 14.4% 51 196 26.0% P¼0.0036 13 91 14% P¼0.98
TNF 380G 208 208 100.0% 99 99 100.0% 91 91 100%
TNF 380A 5 208 2.4% 0 99 0.0% P¼0.12 5 91 5% P¼0.17
The significant results TNF+488 and TNF 859 are highlighted with a grey background.
Table 5 Relationship between grade of tumour at presentation and TNF 859, TNF+488 polymorphism (information available on 191 of 196 patients)
 859T: yes No Population of 191 patients:
G1 (7) 14.0% (43) 30.5% (50) 26.2%
G2 (34) 68.0% (58) 41.1% (92) 48.2%
G3 (9) 18.0% (40) 28.4% (49) 25.6%
50 26.2% 141 73.8% 191
w
2 test  859T vs  859 not T, for G1, G2, G3 P¼0.0043, for G1 vs (G2+G3) P¼0.023
+488A: yes No Population of 191 patients:
G1 (9) 16.7% (41) 29.9% (50) 26.2%
G2 (35) 64.8% (57) 41.6% (92) 48.2%
G3 (10) 18.5% (39) 28.5% (49) 25.6%
54 28.3% 137 71.7% 191
w
2 test +488A vs +488 not A, for G1, G2, G3 P¼0.015, for G1 vs (G2+G3) P¼0.06
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sdemonstrates the presence of a previously unreported haplotype;
one that we hypothesise will have functional significance. Several
TNF haplotypes have already been described involving TNF and
the surrounding lymphotoxin gene (Fanning et al, 1997) and the
surrounding HLA alleles (Wilson et al, 1993). The linkage between
TNFþ488A and TNF 859T that we have demonstrated may help
to clarify further the role of polymorphisms in TNF and may
explain the previously reported disease associations with the
TNFþ488 polymorphism, as TNFþ488 is in the first intron of the
gene and itself noncoding. Interestingly, Verweij (1999) demon-
strated no effect of the TNFþ488 polymorphism on TNFa
production despite demonstrating a clear association with
rheumatoid arthritis, suggesting that the disease associations are
the result of linkage disequilibrium with alleles within or near the
TNF/Lymphotoxin locus.
The mechanisms that could relate polymorphisms that upregu-
late inflammatory pathways to cancer are well recognised (Balkwill
and Mantovani, 2001), including generation of free radicals
(Marshall et al, 2000) and DNA damage (Winsey et al, 2000),
enhanced angiogenesis and also immunosuppressive effects at
higher concentrations. Chronic inflammation of the bladder as
seen in schistosomiasis and long-term catheter use are well-
recognised risk factors for bladder cancer (Locke, 1985; Stonehill,
1996) and inflammation associated with superficial bladder cancer
is a common observation at operation.
In addition to their role in the risk of bladder cancer, we
investigated the role of TNF polymorphisms in tumour behaviour.
We have shown a significant association of both TNFþ488A and
TNF 859T with grade of tumour at presentation. If the presence of
TNFþ488A or TNF 859T affects the development of bladder
tumours to make them generally less well differentiated, then we
would expect to see more G3 as well as G2 tumours. It is possible
that upregulation of TNFa or TNFa-dependent pathways direct the
progression of bladder cancer to grade 2, but other additional
factors are involved in progression from grade 2 to grade 3, in
keeping with the evidence of stepwise progression of bladder
cancer. For example, in other types of cancer, clear upregulation of
oncogenes to cause a specific subtype of disease are recognised egg
AML and ALL.
Finally, there was no association of the TNFþ488A or
TNF 859T polymorphisms with recurrence or progression. This
type of result has been found in other cancer studies of TNF
polymorphisms. For example, in non-Hodgkin’s lymphoma,
although TNF polymorphisms have been shown to influence
treatment outcome, progression-free survival and overall survival
of patients (Warzocha et al, 1998), in myeloma TNF and
lymphotoxin a polymorphisms are associated with increased risk
of the disease, but no overall increase in survival (Davies et al,
2000).
The natural history of G2 tumours is very heterogeneous
and it is this group in particular that needs better prognostic
information. A larger study would be needed to demonstrate
whether TNF genetic variants influence prognosis within the G2
subgroup.
In conclusion, we have demonstrated for the first time a TNF
polymorphism association with risk of bladder cancer and grade of
tumour at presentation. This is a further urological tumour
association involving the polymorphism at position TNFþ488,
which has already been shown to be associated with prostate
cancer. We have also demonstrated an additional TNF haplotype,
which we hypothesise is of functional significance and which may
help clarify the role of SNPs in influencing TNFa protein
expression. If it affects the responsiveness of TNFa production
to toxic stress, then this may explain the relation to risk of bladder
cancer and higher grade and determine the effectiveness of
intravesical BCG. Furthermore, there are now specific inhibitors
of TNFa such as etanercept (Spencer-Green, 2000) and infliximab
(Sands, 1999) which could be investigated.
Further investigation will require a molecular approach analys-
ing the gene promoter in bladder epithelium.
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